Breaking News: Blueberries Medical Appoints Former Colombian Minister & Ambassador Fabio Valencia to Board of Directors | Financial Buzz

Breaking News: Blueberries Medical Appoints Former Colombian Minister & Ambassador Fabio Valencia to Board of Directors

Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the “Company” or “Blueberries“), a leading Colombia-based licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce the appointment of Fabio Valencia Cossio, a former Colombian Minister, Senator and Ambassador to Italy with extensive strategic international business experience to its board of directors.

“We are honored to welcome Mr. Valencia to our board of directors and are confident that his vast experience in public policy and international business will be a valuable addition to our leadership team,” stated Christian Toro, Chief Executive Officer. “His appointment will create competitive advantages through his established track record of success guiding global companies in rapidly evolving regulatory environments. As we look to expand globally and enter new jurisdictions, Mr. Valencia’s international relationships and experience navigating foreign regulatory environments will be invaluable.”

“I look forward to joining the Blueberries team as they continue to execute on their impressive growth strategy and show their leadership in the Colombian market and abroad,” stated Mr. Valencia. “I am confident I will be able to add value as we become a dominant regional player in Latin America and expand internationally.”

Mr. Valencia practiced as a lawyer after graduating from the University of Antioquia before being elected to Colombian congress in 1982. His extensive tenure in public office includes service in the following appointments:

  • Minister of the Interior and Justice of Colombia
  • Ambassador to Italy with dual accreditation to Greece, Malta, San Marino and Cyprus
  • Representative of Colombia to the United Nations Agency in Rome
  • High Presidential Adviser for Competitiveness and Productivity
  • President of the Congress of the Republic of Colombia
  • Senator and Member of House of Colombia Representatives
  • Member of the National Council of Narcotic Drugs
  • Presidential Commissioner for the Plan Puebla-Panama
  • Colombian Representative, Food and Agriculture Organization of the United Nations
  • Peace Negotiator, Colombian Government and FARC
  • Minister Delegate for Presidential Functions of Colombia

Since his tenure with the government, Mr. Valencia has been very active in the private sector where he currently provides legal and commercial consulting services to an extensive group of large multinational companies looking to grow their operations in South America. He is currently engaged with consumer product companies including Diageo plc, Pernod Ricard S.A. and Bacardi Limited. Mr. Valencia has also advised Ribera Salud Spain, a leading provider of health insurance services and Indra Sistemas S.A., Grupo Tradeco, Gilat Satellite Networks, Pacific Rubiales and Gran Colombia Gold.

Mr. Valencia’s distinguished political career spanned 40 years over which time he was an integral member of numerous significant political accomplishments.  As Ambassador to Italy, Mr. Valencia achieved the highest level of diplomatic, commercial and cultural relations. The following is a few of his many achievements. As Minister of the Interior and Justice of Colombia, Mr. Valencia designed a comprehensive policy against the world drug problem and redesigned the national narcotics program. He also designed and implemented several important policies for the protection of human rights as well as a monitoring system for the legislative activity of the National Government in the Congress of Colombia. During his time in the High Council for Competitiveness, he helped to create and implement the national competitiveness system, recognized by the private sector as a great instrument for investment and business development and infrastructure in all regions of the country. Mr. Valencia was also instrumental with ​​the Puebla-Panama Plan, “the Mesoamerica Project”, helping to have Colombia accepted as a full partner in the Mexico-Central America regional block, generating new multilateral opportunities for the Country. As an author he Mr. Valencia has written, “Towards a New Municipality” (1985), “Chronicles of Courage” (1994), “Asia: The Future” (1996), and “Formulas to Save Colombia” (1996). He also co-authored “Freedom of the Press in Colombia”, “Solutions for the Countryside”, and “Insecurity and Impunity in Colombia”, among others.

Mr. Valencia is also a former President of the Shalom Association (Cultural Exchange with Israel) and a Member of the Colombo-Israel Cultural Institute based in Jerusalem.

In recognition of his service, Mr. Valencia has been distinguished with a number of prestigious honors including:

  • Order of San Carlos granted by the National Government of Colombia
  • Order of Merit of the Italian Republic (Knight of Grand Cross) granted by the Italian Republic
  • Order of the Congress of Colombia Gran Cruz degree with gold plaque granted by the Senate

Mr. Valencia has been granted options (the “Options”) to purchase up to 500,000 common shares in the capital of the Company, pursuant to the Company’s stock option plan. The Options are exercisable at a price of $0.55 per share.

About Blueberries Medical Corp.
Blueberries is a Colombia-based licensed producer of naturally grown premium quality cannabis with its primary operations ideally located in the Bogotá Savannah of central Colombia. Led by a specialized team with proprietary expertise in agriculture, genetics, extraction, medicine, pharmacology and marketing, Blueberries is fully licensed for the cultivation, production, domestic distribution, and international export of CBD and THC-based medical cannabis. Blueberries’ combination of leading scientific expertise, agricultural advantages and distribution arrangements has positioned the Company to become a leading international supplier of naturally grown, processed, and standardized medicinal-grade cannabis oil extracts and related products.

Sponsored Content Release. Click for Full Disclosure

  • Sponsored Content Release, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For blueberries medical corp. financial and corporate news dissemination, has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: